Savara Inc. reported a net loss of $26.6 million, or $(0.12) per share, for the first quarter of 2025, compared to a net loss of $20.3 million, or $(0.11) per share, for the first quarter of 2024. This increase in net loss reflects ongoing investments in its lead program.
Research and development expenses increased by 14.0% to $19.2 million in Q1 2025, primarily due to regulatory affairs and quality assurance activities related to MOLBREEVI. General and administrative expenses rose by 64.1% to $9.2 million, driven by higher personnel costs and commercial preparation activities.
As of March 31, 2025, the company had approximately $172.5 million in cash, cash equivalents, and short-term investments, with debt of approximately $29.5 million. Savara believes its current cash runway extends into the second half of 2027, providing funding beyond a potential U.S. launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.